Our Correspondent
The Subject Expert Committee of Central Drugs Standard Control Organisation (CDSCO) that met on January 1 and 2, 2021 has granted the permission to Cadila Healthcare Ltd for conduct of the Phase III clinical trial of the Novel Corona Virus-2019-nCov-Vaccine it has developed.
The firm initiated Phase-I/II clinical trial in India in more than 1,000 participants which is ongoing. The interim data suggests that the vaccine is safe and immunogenic with three doses when administered intradermally. Accordingly, firm has sought permission to conduct Phase-III clinical trial in 26,000 Indian participants, which has been recommended by the Subject Expert Committee.
The approval for the third phase of trials for Cadila Healthcare Ltd came even as the CDSCO approved vaccines of M/s Serum and M/s Bharat Biotech for restricted use in emergency situation.
Joseph Maliakan Seven months of January to July 2025 , witnessed an unprecedented 334 incidents…
Muscat : Set to take place in Muscat this October, the 2025 edition of the…
Dubai: ADNOC Gas has entered into a 10-year agreement to supply liquefied natural gas (LNG)…
Joseph Maliakan In a great relief to political, social and human rights activists in the…
By Joseph MaiakanThe Enforcement Directorate ( ED ) the long arm of the Modi government…
Muscat: The Indian School Al Seeb (ISAS) community is deeply saddened by the passing of…
This website uses cookies.